Oxford and GSK launch £50m programme to advance cancer research
Global biopharma company GSK invests up to £50 million in a collaboration with Oxford to advance the understanding of how cancer develops, which could inform future development of vaccines to prevent cancer.
Read moreLatest News
Rapamycin helps protect immune cells against DNA damage
26 January 2026
What determines the fate of a T cell?
20 January 2026
Upcoming Talks
-
Thursday, 05 February 2026, 11am to 12pm
-
Thursday, 05 February 2026, 3pm to 4pm
-
Friday, 06 February 2026, 9.15am to 10.15am
-
Friday, 06 February 2026, 1pm to 2pm
-
Monday, 09 February 2026, 12.30pm to 1.30pm
-
Tuesday, 10 February 2026, 9.30am to 10.30am
Latest publications
-
Autophagy machinery as exploited by viruses.
Journal article
Münz C. et al, (2025), Autophagy Rep, 4
-
Risk analysis for outpatient experimental infection as a pathway for affordable RSV vaccine development
Journal article
Siegal EZ. et al, (2025), npj Vaccines, 10
-
Influential drivers of the cost-effectiveness of respiratory syncytial virus vaccination in European older adults: a multi-country analysis
Journal article
Li X. et al, (2025), BMC Medicine, 23
-
Computationally designed haemagglutinin with nanocage plug-and-display elicits pan-H5 influenza vaccine responses.
Journal article
Huang CQ. et al, (2025), Emerg Microbes Infect, 14